Switch theme
Sign up to access all valuation multiples
Demant AS is a Denmark-based company engaged in the healthcare industry. The company develops, manufactures and sells products and equipment designed to aid the hearing and communication of individuals. The Group focuses on four business areas: Hearing Devices, including such brands as Bernafon, Oticon, Frontrow, Phonic Ear and Sonic; Hearing Implants, including Oticon Medical; Diagnostic Instruments. The Company operates through more than 90 subsidiaries and associates all around the world. More than 80% of the company's sales come from North America and Europe.
1904
22.6K+
LTM Revenue $3.4B
LTM EBITDA $881M
$10.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Demant has a last 12-month revenue (LTM) of $3.4B and a last 12-month EBITDA of $881M.
In the most recent fiscal year, Demant achieved revenue of $3.4B and an EBITDA of $874M.
Demant expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Demant valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| Gross Profit | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $881M | XXX | $874M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $659M | XXX | $648M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $380M | XXX | $359M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Demant's stock price is DKK 257 (or $39).
Demant has current market cap of DKK 54.7B (or $8.2B), and EV of DKK 69.3B (or $10.4B).
See Demant trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.4B | $8.2B | XXX | XXX | XXX | XXX | $1.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Demant has market cap of $8.2B and EV of $10.4B.
Demant's trades at 3.1x EV/Revenue multiple, and 11.9x EV/EBITDA.
Equity research analysts estimate Demant's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Demant has a P/E ratio of 21.7x.
See valuation multiples for Demant and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.2B | XXX | $8.2B | XXX | XXX | XXX |
| EV (current) | $10.4B | XXX | $10.4B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 11.8x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBIT | 15.9x | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.7x | XXX | 22.9x | XXX | XXX | XXX |
| EV/FCF | 24.8x | XXX | 21.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDemant's last 12 month revenue growth is 5%
Demant's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Demant's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Demant's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Demant and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Demant acquired XXX companies to date.
Last acquisition by Demant was XXXXXXXX, XXXXX XXXXX XXXXXX . Demant acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Demant founded? | Demant was founded in 1904. |
| Where is Demant headquartered? | Demant is headquartered in Denmark. |
| How many employees does Demant have? | As of today, Demant has 22.6K+ employees. |
| Who is the CEO of Demant? | Demant's CEO is Mr. Soren Nielsen. |
| Is Demant publicy listed? | Yes, Demant is a public company listed on CSE. |
| What is the stock symbol of Demant? | Demant trades under DEMANT ticker. |
| When did Demant go public? | Demant went public in 1995. |
| Who are competitors of Demant? | Similar companies to Demant include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Demant? | Demant's current market cap is $8.2B |
| What is the current revenue of Demant? | Demant's last 12 months revenue is $3.4B. |
| What is the current revenue growth of Demant? | Demant revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Demant? | Current revenue multiple of Demant is 3.0x. |
| Is Demant profitable? | Yes, Demant is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Demant? | Demant's last 12 months EBITDA is $881M. |
| What is Demant's EBITDA margin? | Demant's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Demant? | Current EBITDA multiple of Demant is 11.8x. |
| What is the current FCF of Demant? | Demant's last 12 months FCF is $421M. |
| What is Demant's FCF margin? | Demant's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Demant? | Current FCF multiple of Demant is 24.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
